Fig 3.

Functional Assessment of Cancer Therapy–Head and Neck (FACT-HN) scores plotted at four time points (baseline, after induction therapy with docetaxel, cisplatin, and cetuximab and before starting definitive therapy with radiotherapy, cisplatin, and cetuximab [XPE], 3 months after XPE, and 12 months after XPE). Patients reported significantly decreased head and neck–relevant quality of life (-HN subscale score) at 3 months after completion of XPE (P = .012); this difference was no longer evident by 1 year after XPE completion (P = .179).